Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease
- 1 January 2014
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 76, 51-56
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Adenosine A2A receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillationMolecular Psychiatry, 2012
- Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers DiseaseCurrent Pharmaceutical Design, 2010
- Calretinin Interneurons are Early Targets of Extracellular Amyloid-β Pathology in PS1/AβPP Alzheimer Mice HippocampusJournal of Alzheimer’s Disease, 2010
- Caffeine prevents sleep loss‐induced deficits in long‐term potentiation and related signaling molecules in the dentate gyrusEuropean Journal of Neuroscience, 2010
- Age-Dependent Impairment of Spine Morphology and Synaptic Plasticity in Hippocampal CA1 Neurons of a Presenilin 1 Transgenic Mouse Model of Alzheimer's DiseaseJournal of Neuroscience, 2009
- Reduced Expression of the Inhibitory Synapse Scaffolding Protein Gephyrin in Alzheimer's DiseaseJournal of Alzheimer’s Disease, 2008
- Altered synaptic function in Alzheimer's diseaseEuropean Journal of Pharmacology, 2006
- Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapsesNeurobiology of Disease, 2005
- Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategiesProgress in Neurobiology, 2002
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982